1247729-31-2

Upstream product

• 72-19-5 L-threonine 
• 1247729-30-1 6-phenyl-pyridine-2-carbonyl chloride 

Downstream Products

• 847494-64-8 N-[(1S,2R)-1-[[[(1R)-1-1[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]carbonyl]-2-hydroxypropyl]-6-phenyl-2-pyridinecarboxamide 
• 847499-27-8 Delanzomib 

Relevant academic research and scientific papers

Development and scale-up of an optimized route to the peptide boronic acid, CEP-18770

CEP-18770 is an unstable peptide boronic acid and an amorphous solid, making it a challenging synthetic target. Process R&D led to a new process that avoided chromatography through crystalline intermediates, increased atom and volume efficiency, provided

Proteasome inhibitor delanzomib for use in the treatment of lupus

The present invention provides a method for treating lupus in a subject, comprising the step of administering to the subject Compound A.

PROTEASOME INHIBITORS AND PROCESSES FOR THEIR PREPARATION, PURIFICATION AND USE

The invention provides boronic esters of Formula (I) wherein R1, R2, R3, and R4 are as described herein, and methods for the preparation and purification thereof.